Bioatla announces upcoming poster presentation at the iaslc 2024 hot topic in basic & translational science meeting

San diego, dec. 10, 2024 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming international association for the study of lung cancer (iaslc) 2024 hot topic in basic & translational science meeting to be held in washington, dc from december 13–15, 2024.
BCAB Ratings Summary
BCAB Quant Ranking